tert-butyl 3-(5-chloro-2-pyridinyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate | 286946-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 3-(5-chloro-2-pyridinyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
• 英文别名: tert-butyl 3-(5-chloropyridin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
• CAS: 286946-40-5
• 化学式: C₁₆H₂₂ClN₃O₂
• 分子量: 323.823
• InChiKey: OPBALOICVPTYMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  8-BOC-3,8-二氮杂双环[3.2.1]辛烷 、 2,5-二氯吡啶 生成 tert-butyl 3-(5-chloro-2-pyridinyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
  参考文献：
  名称：

  Diazabicyclic CNS active agents

  摘要：

  化合物I的公式或其药学上可接受的盐，对于控制哺乳动物的突触传递是有用的。

  公开号：

  US07265115B2

文献信息

• [EN] INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BCL6 BTB ET LEURS UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019153080A1

  公开（公告）日：2019-08-15

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及公式I（I）化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
  申请人：ABBOTT LABORATORIES

  公开号：EP1359152A2

  公开（公告）日：2003-11-05

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

  式(I)化合物或其药学上可接受的盐 其中 V 选自由共价键和 CH2 组成的组； W 选自由共价键、 和 组成的组； X 选自由共价键和 组成的组； Y 选自由共价键、 和 组成的组； Z 选自 和 及 组成的组； L1 选自由共价键和 ( )n 组成的组； n 为 1-5； R1 选自由(a)、(b)、(c)、(d)、(e)、(f)、(g)、(h)、(i)、(j)、(k)和(l)组成的组； R2 选自氢、烷氧羰基、烷基、氨基烷基、氨基羰基烷基、苄氧羰基、氰基烷基、二氢-3-吡啶基羰基、羟基、羟基烷基、苯氧羰基和-NH2 所组成的组； 可用于控制哺乳动物的突触传递。
• Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US11518764B2

  公开（公告）日：2022-12-06

  The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及式 I 化合物 或其药学上可接受的盐、溶液剂和/或原药，涉及包含这些化合物或其药学上可接受的盐、溶液剂和/或原药的组合物，以及在治疗可通过抑制与 BCL6 BTB 的相互作用来治疗的疾病、失调或病症（如癌症）中的各种用途。
• DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：ABBOTT LABORATORIES

  公开号：EP1147112B1

  公开（公告）日：2003-10-29
• INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US20200331921A1

  公开（公告）日：2020-10-22

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.